TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24673675

Group type: EXPERIMENTAL
Intervention: Telephone call follow-up by a nurse
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo call (patient satisfaction survey)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no call)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (intervention, placebo, control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Economic analysis of the intervention
Number of subjects: 120
Study: 22094911

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 348

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 348
Study: 21050476

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/20 mg (EZ/Simva)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg (Rosuva)
Number of subjects: 618
Study: 17577218

Group type: EXPERIMENTAL
Intervention: Ixabepilone 35 mg/m² intravenously every 3 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Mitoxantrone 14 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Third-line crossover treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 82
Study: 15037444

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 99
Study: 11358775

Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 3764

Group type: EXPERIMENTAL
Intervention: Summary Card
Number of subjects: 3764

Group type: COMPARATOR
Intervention: Control (surgery access times)
Number of subjects: 3764
Study: 9479724

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 120
Study: 8058226

Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 203

Group type: COMPARATOR
Intervention: Chlorhexidine gluconate
Number of subjects: 203
Study: 3133709

Group type: EXPERIMENTAL
Intervention: 150 mg trazodone nocte
Number of subjects: 182

Group type: COMPARATOR
Intervention: 50 mg trazodone t.d.s.
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both dosing regimens
Number of subjects: 182
Study: 31834852

Group type: EXPERIMENTAL
Intervention: Mothers with low VZ-IgG (<100 mIU/dL)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Mothers with high VZ-IgG (>100 mIU/dL)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Newborns with low VZ-IgG
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Newborns with high VZ-IgG
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Mothers with past VZV infection
Number of subjects: 350
Study: 29298706

Group type: EXPERIMENTAL
Intervention: Minimally invasive pancreatoduodenectomy (MIPD)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy
Number of subjects: 136
Study: 27178002

Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) of the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 18
Study: 26412680

Group type: EXPERIMENTAL
Intervention: TANDEMplus communication training
Number of subjects: 254

Group type: COMPARATOR
Intervention: TANDEM communication training
Number of subjects: 254
Study: 24021501

Group type: EXPERIMENTAL
Intervention: EEG neurofeedback
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo neurofeedback
Number of subjects: 41
Study: 21399651

Group type: EXPERIMENTAL
Intervention: HBV-positive men undergoing ICSI
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: HBV-positive men undergoing IVF
Number of subjects: 916

Group type: COMPARATOR
Intervention: HBV-negative men undergoing ICSI
Number of subjects: 916

Group type: COMPARATOR
Intervention: HBV-negative men undergoing IVF
Number of subjects: 916
Study: 18804577

Group type: EXPERIMENTAL
Intervention: RhBMP-7
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 30
Study: 16831143

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day for 3 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (immediate surgery)
Number of subjects: 90
Study: 12746164

Group type: EXPERIMENTAL
Intervention: Conventional treatment (daily iron administration)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (iron administration 2 days a week)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (23 children with compatible age and gender distribution)
Number of subjects: 94
Study: 10588216

Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8724062

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg/day in one daily dose)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/kg/day divided into 3 daily doses)
Number of subjects: 210
Study: 1927862

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 7037030

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study: 31446847

Group type: EXPERIMENTAL
Intervention: Transport directly to a comprehensive stroke center for intravenous thrombolysis and endovascular therapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Transport to a primary stroke center for intravenous thrombolysis and subsequent transport to a comprehensive stroke center for endovascular therapy if needed
Number of subjects: 600
Study: 31519320

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily for up to 24 months
Number of subjects: 940

Group type: COMPARATOR
Intervention: Placebo for up to 24 months
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 940

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study: 26423728

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26331961

Group type: EXPERIMENTAL
Intervention: Information about n-3 and CLA (n=325)
Number of subjects: 647

Group type: COMPARATOR
Intervention: No information about n-3 and CLA (n=322)
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Both groups (n=647)
Number of subjects: 647
Study: 24954228

Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m² and cisplatin 75 mg/m² on day 1 (arm A)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 80 mg/m² on days 1 and 8 (first cycle 60 mg/m²) and cisplatin 80 mg/m² on day 1 (arm B)
Number of subjects: 153
Study: 22642740

Group type: EXPERIMENTAL
Intervention: Fixed dose atenolol plus fixed dose losartan
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (atenolol + losartan and placebo)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 26
Study: 19788366

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 242

Group type: COMPARATOR
Intervention: Present‐Centered Therapy
Number of subjects: 242
Study: 18087186

Group type: EXPERIMENTAL
Intervention: Modified automated algorithm
Number of subjects: 77

Group type: COMPARATOR
Intervention: Manual algorithm
Number of subjects: 77
Study: 14684783

Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 447

Group type: COMPARATOR
Intervention: Stroke team
Number of subjects: 447

Group type: COMPARATOR
Intervention: Domiciliary care
Number of subjects: 447
Study: 11488997

Group type: EXPERIMENTAL
Intervention: Surgical sampling (SA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Lymphadenectomy (LY)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2, six cycles repeated every 28 days)
Number of subjects: 202
Study: 10442510

Group type: EXPERIMENTAL
Intervention: 150 mg once weekly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg once weekly
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study: 7587033

Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g twice daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2 g twice daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cefotaxime (various dosages)
Number of subjects: 240
Study: 2262233

Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral indomethacin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 6769156

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744
Study: 31668888

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 759
Study: 30572436

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 132
Study: 27816925

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 24944249

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22067384

Group type: EXPERIMENTAL
Intervention: alemtuzumab
Number of subjects: 95

Group type: COMPARATOR
Intervention: rabbit ATG + cyclosporine
Number of subjects: 95
Study: 20150021

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg every 15 days)
Number of subjects: 22
Study: 18523572

Group type: EXPERIMENTAL
Intervention: Brace on both ankles (intervention group)
Number of subjects: 37
Study: 15718179

Group type: EXPERIMENTAL
Intervention: Extended 6-month heart failure program (EP; n=62)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard 3-month heart failure program (SP; n=68)
Number of subjects: 130
Study: 15569555

Group type: EXPERIMENTAL
Intervention: First questionnaire administered to first 50 randomly selected patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Second questionnaire administered to second group of randomly selected 50 patients
Number of subjects: 100
Study: 11030484

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 to 600 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 90
Study: 8997582

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control
Number of subjects: 86
Study: 1308526

Group type: EXPERIMENTAL
Intervention: Daily rifampicin for 9 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard WHO multidrug regimen (pulsed doses of rifampicin)
Number of subjects: 0
Study: 6146390

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.07 mg/kg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous midazolam 0.2 mg/kg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous thiopentone 3.0 mg/kg
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous ketamine 2.0 mg/kg
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 89
Study: 3739803

Group type: EXPERIMENTAL
Intervention: Smoking allowed in low arousal condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Smoking not allowed in low arousal condition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Smoking allowed
Number of subjects: 24

Group type: COMPARATOR
Intervention: Smoking not allowed
Number of subjects: 24
Study: 31244376

Group type: EXPERIMENTAL
Intervention: Supervised resistance training programme for 16 weeks, 2 sessions per week
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 29309578

Group type: EXPERIMENTAL
Intervention: Intervention based on an evidence-based framework for successful CHW programmes
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intensive supervision and mentoring
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Provision of job aids, standardized manuals, and refresher training
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Formalized links between clinics and CHWs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Concerns raised by CHWs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intensive supervision and integration with clinical services
Number of subjects: 19
Study: 26458973

Group type: EXPERIMENTAL
Intervention: Simultaneous whole-body vibration (WBV) and electromyostimulation (ES)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-body vibration (WBV)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Electromyostimulation (ES)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 30 s of WBV followed by 30 s of ES (WBV30/ES30)
Number of subjects: 10
Study: 24903230

Group type: EXPERIMENTAL
Intervention: Inspiration level defined as segmented total lung volume (TLV) divided by predicted total lung capacity (pTLC)
Number of subjects: 961
Study: 22217432

Group type: EXPERIMENTAL
Intervention: High-frequency (15 Hz) rTMS treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 20298557

Group type: EXPERIMENTAL
Intervention: Group motivational intervention (32 group sessions, 1 to 12 fortnightly, and 13 to 32 monthly)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual follow up (control group) with regular visits every 3 months
Number of subjects: 1200
Study: 18340565

Group type: EXPERIMENTAL
Intervention: High salt diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Medium salt diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low salt diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ABCB1 2677TT/3435TT haplotype
Number of subjects: 10
Study: 15966617

Group type: EXPERIMENTAL
Intervention: Televisite system used for 6 weeks after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Televisite system
Number of subjects: 0
Study: 12685636

Group type: EXPERIMENTAL
Intervention: Pyrethroid-impregnated bed nets
Number of subjects: 103

Group type: COMPARATOR
Intervention: Unimpregnated bed nets
Number of subjects: 103
Study: 10896011

Group type: EXPERIMENTAL
Intervention: Walking with 30% body weight support (BWS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Walking with 0% body weight support (BWS)
Number of subjects: 18
Study: 8834097

Group type: EXPERIMENTAL
Intervention: d‐chlorpheniramine (4 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1419592

Group type: EXPERIMENTAL
Intervention: Brochure with illustrations and narrative text style
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brochure with bullet-type text and no illustrations
Number of subjects: 100
Study: 3831972

Group type: EXPERIMENTAL
Intervention: Caerulein, 1 ng/kg IV
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Caerulein, 75 ng/kg intramuscularly
Number of subjects: 107
Study: 30785408

Group type: EXPERIMENTAL
Intervention: Electronic diary (e-diary) usage
Number of subjects: 89
Study: 30352518

Group type: EXPERIMENTAL
Intervention: Online yoga intervention (60 min/week for 12 weeks)
Number of subjects: 39
Study: 28446846

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (walking on treadmill, three times weekly until the end of 37 weeks of gestation) with diet control
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet control with usual care given by obstetricians and midwives
Number of subjects: 40
Study: 24518078

Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg
Number of subjects: 46
Study: 22281165

Group type: EXPERIMENTAL
Intervention: 0.5% INCB018424 phosphate cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0% INCB018424 phosphate cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5% INCB018424 phosphate cream (twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate 0.05% cream
Number of subjects: 0
Study: 20175820

Group type: EXPERIMENTAL
Intervention: Bromotetrandrine (BrTet) 10 mg/m²
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bromotetrandrine (BrTet) 20 mg/m²
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bromotetrandrine (BrTet) 30 mg/m²
Number of subjects: 30
Study: 17099077

Group type: EXPERIMENTAL
Intervention: 500 microg ipratropium bromide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16164589

Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trial (RCT)
Number of subjects: 0
Study: 12039122

Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism (T allele)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: MTHFR genotype frequencies
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Serum homocysteine levels
Number of subjects: 207
Study: 11088064

Group type: EXPERIMENTAL
Intervention: Preoperative endocrine therapy (3 to 4 months duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 8803300

Group type: EXPERIMENTAL
Intervention: Lisinopril with or without diuretics
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nifedipine with or without diuretics
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Conventional therapy (diuretics with or without vasodilators or selective beta-blockers)
Number of subjects: 76
Study: 1385827

Group type: EXPERIMENTAL
Intervention: High sun exposure and low CD4/CD8 ratio
Number of subjects: 61

Group type: COMPARATOR
Intervention: Low sun exposure and high CD4/CD8 ratio
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Prior basal cell carcinoma and sun exposure
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Low CD4/CD8 ratio
Number of subjects: 61
Study: 6364896

Group type: EXPERIMENTAL
Intervention: Human IgE pentapeptide (HEPP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 12
Study: 29807945

Group type: EXPERIMENTAL
Intervention: Iodine-containing contrast (0.3 mL)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 41
Study: 29183947

Group type: EXPERIMENTAL
Intervention: Intervention group (n=370) reduced worktime to 75% with preserved salary during 18 months
Number of subjects: 636
Study: 28607880

Group type: EXPERIMENTAL
Intervention: Autologous conchal cartilage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Homologous septal cartilage
Number of subjects: 100
Study: 26655888

Group type: EXPERIMENTAL
Intervention: Kefir-fermented milk (1,600 mg) supplemented with calcium bicarbonate (CaCO3, 1,500 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium bicarbonate (CaCO3, 1,500 mg) alone (control)
Number of subjects: 40
Study: 23605599

Group type: EXPERIMENTAL
Intervention: Low-power laser treatment
Number of subjects: 24
Study: 22216772

Group type: EXPERIMENTAL
Intervention: Interactive voice recognition (IVR) intervention designed to prompt medication refills and improve ICS adherence
Number of subjects: 8517

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: Interactive voice recognition (IVR) intervention with 2 or more direct contacts or detailed messages
Number of subjects: 8517
Study: 18482632

Group type: EXPERIMENTAL
Intervention: Cold-pack therapy (vasoconstriction)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sandbag application (compression-control)
Number of subjects: 50
Study: 17135646

Group type: EXPERIMENTAL
Intervention: Oral topotecan (2.3 mg/m2/d, days 1 through 5, every 21 days) plus best supportive care (BSC)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Oral topotecan
Number of subjects: 141
Study: 12709112

Group type: EXPERIMENTAL
Intervention: Frequent pad changing regime
Number of subjects: 81

Group type: COMPARATOR
Intervention: Less frequent pad changing regime
Number of subjects: 81
Study: 11132072

Group type: EXPERIMENTAL
Intervention: Propacetamol 20 mg/kg i.v.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Piritramide 0.25 mg/kg i.m.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg i.v.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Diclofenac 1 mg/kg i.v.
Number of subjects: 160
Study: 9252957

Group type: COMPARATOR
Intervention: Fish diet group (eating fish meals five times per week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: DHA oil group (1.68 g/d DHA in triglyceride form)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fish oil group (1.33 g EPA and 0.95 g DHA/d as free fatty acids)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 8162238

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study: 3526532

Group type: EXPERIMENTAL
Intervention: Amoxycillin (62 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pivampicillin (80 mg/kg/day)
Number of subjects: 20
Study: 30340388

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Health Star Rating system (HSR)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Warning symbol
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 12000